SEOM clinical guideline for the management of immune-related adverse events in patients treated with immune checkpoint inhibitors (2019)
Uloženo v:
| Název: | SEOM clinical guideline for the management of immune-related adverse events in patients treated with immune checkpoint inhibitors (2019) |
|---|---|
| Autoři: | M. Majem, E. García-Martínez, M. Martinez, E. Muñoz-Couselo, D. Rodriguez-Abreu, R. Alvarez, A. Arance, A. Berrocal, L. de la Cruz-Merino, J. A. Lopez-Martin |
| Přispěvatelé: | Institut Català de la Salut, [Majem M] Department of Medical Oncology, Hospital de la Santa Creu i Sant Pau, c/Sant Antoni Maria Claret 167, 08025 Barcelona, Spain. Spanish Group for Cancer Immuno-Biotherapy, GÉTICA, Madrid, Spain. [García-Martínez E] Department of Medical Oncology and Hematology, Hospital Universitario Morales Meseguer, Murcia, Spain. Spanish Group for Cancer Immuno-Biotherapy, GÉTICA, Madrid, Spain. [Martinez M] Department of Medical Oncology, Hospital del Mar, Barcelona, Spain. [Muñoz-Couselo E] Servei de Medicina Oncològica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Melanoma and Other Skin Tumors Unit, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. [Rodriguez-Abreu D] Department of Medical Oncology, C.H.U. Insular-Materno Infantil de Gran Canaria, Las Palmas, Spain. Spanish Group for Cancer Immuno-Biotherapy, GÉTICA, Madrid, Spain. [Alvarez R] Department of Medical Oncology, Hospital Virgen de la Salud, Toledo, Spain, Vall d'Hebron Barcelona Hospital Campus, Universitat Autònoma de Barcelona |
| Zdroj: | Clinical & Translational Oncology r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau Institut dInvestigació Biomèdica Sant Pau (IIB Sant Pau) CLINICAL & TRANSLATIONAL ONCOLOGY r-FIHGUV. Repositorio Institucional de Producción Científica de la Fundación de Investigación del Hospital General de Valencia instname Scientia Scientia. Dipòsit d'Informació Digital del Departament de Salut Repositorio Institucional de la Consejería de Sanidad de la Comunidad de Madrid Consejería de Sanidad de la Comunidad de Madrid RISalud-ANDALUCIA. Repositorio Institucional de Salud de Andalucía Dipòsit Digital de Documents de la UAB Universitat Autònoma de Barcelona Fundación de Investigación del Hospital General de Valencia (FIHGUV) |
| Informace o vydavateli: | Springer Science and Business Media LLC, 2020. |
| Rok vydání: | 2020 |
| Témata: | 0301 basic medicine, Drug-Related Side Effects and Adverse Reactions, Immunoteràpia - Efectes secundaris, Medical Oncology, Otros calificadores::Otros calificadores::Otros calificadores::/efectos adversos, DISEASES::Neoplasms, 03 medical and health sciences, Antineoplastic Agents, Immunological, 0302 clinical medicine, ATENCIÓN DE SALUD::administración de los servicios de salud::calidad de la atención sanitaria::garantía de calidad de la atención sanitaria::directrices como asunto::guías de práctica clínica como asunto, Neoplasms, Humans, IrAEs, ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Therapeutics::Biological Therapy::Immunomodulation::Immunotherapy, Societies, Medical, TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::terapéutica::terapia biológica::inmunomodulación::inmunoterapia, Clinical Trials as Topic, Toxicity, Càncer - Tractament, Disease Management, 3. Good health, HEALTH CARE::Health Services Administration::Quality of Health Care::Quality Assurance, Health Care::Guidelines as Topic::Practice Guidelines as Topic, Other subheadings::Other subheadings::Other subheadings::/adverse effects, ENFERMEDADES::neoplasias, Practice Guidelines as Topic, irAEs, Protocols clínics, Immunotherapy |
| Popis: | The use of immune checkpoint inhibitors has emerged as an effective treatment option for patients with several tumor types. By increasing the activity of the immune system, they can induce inflammatory side effects, which are often termed immune-related adverse events. These are pathophysiologically unique toxicities, compared with those from other anticancer therapies. In addition, the spectrum of the target organs is very broad. Immune-inflammatory adverse events can be life threatening. Prompt diagnosis and pharmacological intervention are instrumental to avoid progression to severe manifestations. Consequently, clinicians require new skills to successfully diagnose and manage these events. These SEOM guidelines have been developed with the consensus of ten medical oncologists. Relevant studies published in peer-review journals were used for the guideline elaboration. The Infectious Diseases Society of America grading system was used to assign levels of evidence and grades of recommendation. |
| Druh dokumentu: | Article |
| Popis souboru: | application/pdf |
| Jazyk: | English |
| ISSN: | 1699-3055 1699-048X |
| DOI: | 10.1007/s12094-019-02273-x |
| Přístupová URL adresa: | https://link.springer.com/content/pdf/10.1007/s12094-019-02273-x.pdf https://pubmed.ncbi.nlm.nih.gov/31993963 https://iibsantpau.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=1524 http://hdl.handle.net/10230/47133 https://fundanet.fihgu.san.gva.es/publicaciones/ProdCientif/PublicacionFrw.aspx?id=1524 https://hdl.handle.net/11351/6313 https://hdl.handle.net/20.500.12530/61703 http://hdl.handle.net/10668/15018 https://iibsantpau.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=1524 https://fihguv.fundanetsuite.com/publicaciones/ProdCientif/PublicacionFrw.aspx?id=1524 https://jglobal.jst.go.jp/en/detail?JGLOBAL_ID=202002229543692850 https://repositori.upf.edu/handle/10230/47133 https://link.springer.com/content/pdf/10.1007/s12094-019-02273-x.pdf https://pubmed.ncbi.nlm.nih.gov/31993963/ https://link.springer.com/article/10.1007/s12094-019-02273-x https://dialnet.unirioja.es/servlet/articulo?codigo=7254521 https://hdl.handle.net/10668/15018 |
| Rights: | CC BY |
| Přístupové číslo: | edsair.doi.dedup.....6c6abd323d423164ebf7029c9debec51 |
| Databáze: | OpenAIRE |
Full Text Finder 
Nájsť tento článok vo Web of Science | Abstrakt: | The use of immune checkpoint inhibitors has emerged as an effective treatment option for patients with several tumor types. By increasing the activity of the immune system, they can induce inflammatory side effects, which are often termed immune-related adverse events. These are pathophysiologically unique toxicities, compared with those from other anticancer therapies. In addition, the spectrum of the target organs is very broad. Immune-inflammatory adverse events can be life threatening. Prompt diagnosis and pharmacological intervention are instrumental to avoid progression to severe manifestations. Consequently, clinicians require new skills to successfully diagnose and manage these events. These SEOM guidelines have been developed with the consensus of ten medical oncologists. Relevant studies published in peer-review journals were used for the guideline elaboration. The Infectious Diseases Society of America grading system was used to assign levels of evidence and grades of recommendation. |
|---|---|
| ISSN: | 16993055 1699048X |
| DOI: | 10.1007/s12094-019-02273-x |